Facebook Instagram X-twitter Linkedin Youtube Spotify Apple
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 13, 2025
ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Givinostat Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy
August 26, 2025

PTC: Update to the U.S. Duchenne Community on the Ataluren (Translarna) NDA Review

August 19, 2025

On August 11, 2025, PTC Therapeutics shared a community update about the status of the Ataluren FDA filing, the first potential therapy specifically for individuals with nonsense mutation Duchenne.

To view their community update, please click here.

Register Now

Experience the magic this summer!

Apply Today

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Register Today

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Give Today

Accessible Vehicle Fund Applications Open

Apply Today